Orange Book product · Brand (NDA)
TARGRETIN
BEXAROTENE
At a glance
Dec 29, 1999
Approved
Brand (NDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Dec 29, 1999
26 yr 10 mo ago
Today
Pharmaceutical detail
Active ingredient
BEXAROTENE
Strength
75MG
Dosage form
CAPSULE
Route
ORAL
TE code
AB
Application
NDA 021055
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2000TARGRETINBrand (NDA)
NDA 021056 · BAUSCH
- 2024BEXAROTENEGeneric (ANDA)
ANDA 210352 · CIPLA
- 2024BEXAROTENEGeneric (ANDA)
ANDA 208628 · ASCENT PHARMS INC
- 2022BEXAROTENEGeneric (ANDA)
ANDA 215398 · AMNEAL
- 2021BEXAROTENEGeneric (ANDA)
ANDA 209931 · TEVA PHARMS USA
- 2020BEXAROTENEGeneric (ANDA)
ANDA 203663 · HIKMA
- 2018BEXAROTENEGeneric (ANDA)
ANDA 210105 · AMNEAL PHARMS NY
- 2018BEXAROTENEGeneric (ANDA)
ANDA 209886 · UPSHER SMITH LABS
- 2018BEXAROTENEGeneric (ANDA)
ANDA 209861 · ANI PHARMS
- 2014BEXAROTENEGeneric (ANDA)
ANDA 203174 · BIONPHARMA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
